

Gimsilumab

Cat. No.:	HY-P99642
CAS No.:	1648796-29-5
Target:	c-Fms; SARS-CoV
Pathway:	Protein Tyrosine Kinase/RTK; Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Gimsilumab (MORAb-022) is a human anti-GM-CSF monoclonal antibody. Gimsilumab has the potential for the research of COVID-19 and rheumatoid arthritis (RA)^{[1][2]}.

REFERENCES

- [1]. Criner GJ, et al. Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial. *Am J Respir Crit Care Med*. 2022 Jun 1;205(11):1290-1299.
- [2]. Crotti C, et al. Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date. *Drug Des Devel Ther*. 2017 Jan 13;11:211-223.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA